Merck said Saturday its new pill — a potential rival to Regeneron and Amgen — lowered stubbornly high cholesterol by almost ...

Regeneron and Sanofi’s Dupixent trial shows major improvement in allergic fungal rhinosinusitis symptoms in patients 6+. Read ...

Shares of Regeneron Pharmaceuticals Inc. REGN rallied 2.58% to $644.19 Wednesday, on what proved to be an all-around great ...

Wondering if Regeneron Pharmaceuticals is a hidden gem or just fairly priced? You are not alone; investors everywhere are ...

Michael Burry boosted his positions in apparel, healthcare, and scientific stocks, while trimming major holdings, showing a ...

According to Benzinga Pro, Regeneron Pharmaceuticals Inc's peer group average for short interest as a percentage of float is ...

Regeneron Pharmaceuticals (REGN) is forecasting annual earnings growth of 7.41%, with revenue also projected to rise by 7% ...

Regeneron Pharmaceuticals recently completed a study titled Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept 2 mg: A US Real-World Evidence Study Using the IRIS Registry. The study ...

Discover Regeneron’s Q3 2025 earnings: strong Dupixent, Libtayo & EYLEA HD growth, R&D updates, plus key manufacturing and regulatory challenges.

Shares of biotech company Regeneron (NASDAQ:REGN) jumped 8.7% in the morning session after it reported third-quarter ...

Learn more about whether Alnylam Pharmaceuticals, Inc. or Avidity Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Stock futures were little changed Tuesday, a day after major indexes set fresh intraday and closing records for a second straight session, as a highly anticipated Federal Reserve meeting was set to ...